{"result": "(\"entity\"<|>ABBOTT<|>ORGANIZATION<|>Abbott is a global healthcare company that produces various nutritional products, including Nepro HP and Oxepa.)\n##\n(\"entity\"<|>FRESENIUS KABI<|>ORGANIZATION<|>Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies, including nutritional products like Intestamin and Supportan.)\n##\n(\"entity\"<|>NUTRICIA<|>ORGANIZATION<|>Nutricia is a specialized nutrition company that produces various nutritional products, including Nutrison Advanced Cubison.)\n##\n(\"entity\"<|>NESTLÉ<|>ORGANIZATION<|>Nestlé is a multinational food and beverage company that produces various nutritional products, including Impact Enteral.)\n##\n(\"entity\"<|>VEGENAT<|>ORGANIZATION<|>Vegenat is a company that specializes in plant-based nutritional products, including Atémpero Enteral.)\n##\n(\"relationship\"<|>NEPRO HP<|>ABBOTT<|>Nepro HP is a nutritional product manufactured by Abbott<|>9)\n##\n(\"relationship\"<|>OXEPA<|>ABBOTT<|>Oxepa is a nutritional product manufactured by Abbott<|>9)\n##\n(\"relationship\"<|>PULMOCARE<|>ABBOTT<|>Pulmocare is a nutritional product manufactured by Abbott<|>9)\n##\n(\"relationship\"<|>INTESAMIN<|>FRESENIUS KABI<|>Intestamin is a nutritional product manufactured by Fresenius Kabi<|>9)\n##\n(\"relationship\"<|>SUPPORTAN<|>FRESENIUS KABI<|>Supportan is a nutritional product manufactured by Fresenius Kabi<|>9)\n##\n(\"relationship\"<|>NUTRISON ADVANCED CUBISON<|>NUTRICIA<|>Nutrison Advanced Cubison is a nutritional product manufactured by Nutricia<|>9)\n##\n(\"relationship\"<|>IMPACT ENTERAL<|>NESTLÉ<|>Impact Enteral is a nutritional product manufactured by Nestlé<|>9)\n##\n(\"relationship\"<|>ATÉMPERO ENTERAL<|>VEGENAT<|>Atémpero Enteral is a nutritional product manufactured by Vegenat<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 1,3 | Bolsa 500 ml Neutro Botella 500 ml Chocolate | 395 | 30,7 (12%) AA de cadena ramificada (40%) y AA aromáticos (21%) | 119,2 (47%) Almidón, DXM | 44,6 (40%) Coco, Soja, 50% MCT | 700 1300 | 4,6 (1%) |\n| INSUFICIENCIA RENAL | Nepro HP | Abbott | 1,8 | Botella 500 ml | 538 | 45 (18%) Caseína | 81 (33%) Almidón | 54,2 (49%) Girasol rico en oleico 65%, Cánola 31% | 388 588 | Fibersol, Probióticos (fructoligosacáridos) |\n| INSUFICIENCIA RESPIRATORIA AGUDA | Oxepa | Abbott | 1,52 | Botella 500 ml Neutro | 384 | 41,1 (16,5%) Caseína | 69,7 (30%) DXM, Sacarosa | 61,6 (55,5%) 25% MCT 29% Mono | 850 1300 | 0 GLA, EPA |\n---\n| 1014 | Anexo 5. Fórmulas enterales para infusión por sonda más empleadas en nuestro medio |\n|------|----------------------------------------------------------------------------|\n\n| Grupo | Producto® | Empresa | Kcal/ ml | Presentación | Osmol | Proteínas g/1000 kcal (%) | Hidratos de carbono g/1000 kcal (%) | Lípidos g/1000 kcal (%) | Sodio Potasio mg/1000 kcal | Otros g Fibra/1000 kcal (sol/insol) Caract. espec. |\n|-------|-----------|----------|----------|--------------|-------|---------------------------|--------------------------------------|-------------------------|----------------------------|---------------------------------------------------|\n| INSUFICIENCIA RESPIRATORIA CRÓNICA | Pulmocare | Abbott | 1,51 | Botella 500 ml Lata 250 ml | 383 | 44,4 (16,5%) Caseína | 70 (30%) Sacarosa | 61,8 (55,5%) 20% MCT 44% Mono; ω6/ω3 = 3,8 | 850 1300 | 0 |\n| | Perative RTH | Abbott | 1,31 | Botella 1000 ml Neutro | 308 | 51,1 (20,5%) Hidrolizado lactosuero y Caseína | 135,1 (54%) DXM | 28,2 (25,5%) 40% MCT 29% Mono; ω6/ω3 = 4,7 | 800 1300 | 0 L-arginina |\n| INMUNOMODULADORAS | Intestamin | Fresenius Kabi | 0,5 | EasyBag 500 ml Neutro | 390 | 170 (68%) Dipéptidos L-alanil-L-glutamina, glicil-L-glutamina | 75 (30%) DXM | 4 (2%) Tributirina | 1850 1050 | 0 |\n| | Nutrison Advanced Cubison | Nutricia | 1,04 | Pack 1000 ml Vainilla | 315 | 52,9 (22%) Caseína, L-Arginina | 120 (47%) | 31,2 (28%) 27% MCT, 42% Mono; ω6/ω3 = 5,26 | 960 1440 | 14,4 (47/53) (3%) Arginina, Vitaminas A C E, Zn, Carotenoides |\n| | Impact Enteral | Nestlé | 1,01 | Smartflex 500 ml Neutro | 298 | 55,4 (22%) Caseína, L-arginina | 132,6 (53%) DXM | 27,7 (25%) 38% Vegetal, 40% Pescado, 22% MCT | 1050 1330 | 0 Zn, Se, vit A, vit C, vit E 12,8 g L-arginina, 3 g Omega-3 |\n| | Atémpero Enteral | Vegenat | 1,25 | Pack 500 ml Vainilla | 400 | 57,6 (23%) Caseína, Vegetal, Sérica | 97,6 (39%) DXM | 39,2 (35%) Vegetal, Pescado, 9% MCT, 47% Mono, DHA + EPA; ω6/ω3 = 1,48 | 800 1600 | 13,6 (100/0) (3%) FOS L-arginina, Nucleótidos |\n| | Supportan | Fresenius Kabi | 1,5 | EasyBag 500 ml Neutro | 340 | 66,6 (27%) Leche | 78,6 (31%) Dextrinomaltosa, Sacarosa | 44,6 (40%) Colza, Girasol, Pescado, 34% MCT, 21% Mono; ω6/ω3 = 1,5 | 300 850 | 8\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>BOLSA 500 ML NEUTRO BOTELLA 500 ML CHOCOLATE<|>EVENT<|>A product related to nutritional formulas, specifically a chocolate-flavored liquid in a 500 ml bottle, used for dietary purposes.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL<|>EVENT<|>A medical condition that requires specific nutritional support, often treated with specialized formulas like Nepro HP.)\n##\n(\"entity\"<|>NEPRO HP<|>ORGANIZATION<|>A nutritional product designed for patients with renal insufficiency, produced by Abbott.)\n##\n(\"entity\"<|>INSUFICIENCIA RESPIRATORIA AGUDA<|>EVENT<|>A critical medical condition that necessitates specialized nutritional support, often treated with products like Oxepa.)\n##\n(\"entity\"<|>OXEPA<|>ORGANIZATION<|>A nutritional product designed for patients with acute respiratory insufficiency, produced by Abbott.)\n##\n(\"entity\"<|>INSUFICIENCIA RESPIRATORIA CRÓNICA<|>EVENT<|>A chronic medical condition that requires ongoing nutritional support, often treated with products like Pulmocare.)\n##\n(\"entity\"<|>PULMOCARE<|>ORGANIZATION<|>A nutritional product designed for patients with chronic respiratory insufficiency, produced by Abbott.)\n##\n(\"entity\"<|>INMUNOMODULADORAS<|>EVENT<|>A category of nutritional products aimed at modulating immune response, often used in clinical settings.)\n##\n(\"entity\"<|>INTESTAMIN<|>ORGANIZATION<|>A nutritional product aimed at immune modulation, produced by Fresenius Kabi.)\n##\n(\"entity\"<|>NUTRISON ADVANCED CUBISON<|>ORGANIZATION<|>A nutritional product designed for advanced dietary needs, produced by Nutricia.)\n##\n(\"entity\"<|>IMPACT ENTERAL<|>ORGANIZATION<|>A nutritional product designed for enteral feeding, produced by Nestlé.)\n##\n(\"entity\"<|>ATÉMPERO ENTERAL<|>ORGANIZATION<|>A nutritional product designed for enteral feeding, produced by Vegenat.)\n##\n(\"entity\"<|>SUPPORTAN<|>ORGANIZATION<|>A nutritional product designed for dietary support, produced by Fresenius Kabi.)\n##\n(\"relationship\"<|>NEPRO HP<|>INSUFICIENCIA RENAL<|>Nepro HP is a nutritional product specifically designed to support patients with renal insufficiency<|>8)\n##\n(\"relationship\"<|>OXEPA<|>INSUFICIENCIA RESPIRATORIA AGUDA<|>Oxepa is a nutritional product specifically designed to support patients with acute respiratory insufficiency<|>8)\n##\n(\"relationship\"<|>PULMOCARE<|>INSUFICIENCIA RESPIRATORIA CRÓNICA<|>Pulmocare is a nutritional product specifically designed to support patients with chronic respiratory insufficiency<|>8)\n##\n(\"relationship\"<|>INTESTAMIN<|>INMUNOMODULADORAS<|>Intestamin is a nutritional product aimed at immune modulation, fitting within the category of immunomodulatory products<|>7)\n##\n(\"relationship\"<|>NUTRISON ADVANCED CUBISON<|>INMUNOMODULADORAS<|>Nutrison Advanced Cubison is a nutritional product that serves advanced dietary needs, relevant to immunomodulatory support<|>6)\n##\n(\"relationship\"<|>IMPACT ENTERAL<|>INMUNOMODULADORAS<|>Impact Enteral is a nutritional product designed for enteral feeding, which can also be relevant in immunomodulatory contexts<|>6)\n##\n(\"relationship\"<|>ATÉMPERO ENTERAL<|>INMUNOMODULADORAS<|>Atémpero Enteral is a nutritional product designed for enteral feeding, relevant to immunomodulatory needs<|>6)\n##\n(\"relationship\"<|>SUPPORTAN<|>INMUNOMODULADORAS<|>Supportan is a nutritional product designed for dietary support, which can be relevant in immunomodulatory contexts<|>6)\n<|COMPLETE|>"}]}